Review of NICE Technology Appraisal Guidance No. 29; Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia

The Institute was proposing that the guidance should be transferred to the static list.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

Consequently, TA29 will be moved to the static list. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

December 2013